WHO R&D Blueprint Technical Advisory Group prioritizes therapeutics for Bundibugyo virus disease (iris.who.int)

• TAG prioritizes MBP-134, maftivimab, and remdesivir for BVD treatment trials
• Obeldesivir prioritized for post-exposure prophylaxis
• Inmazeb (PALM trial) cited as evidence for maftivimab

"The WHO R&D Blueprint Technical Advisory Group met on 20 and 26 May 2026 to prioritize therapeutics for Bundibugyo virus disease (BVD) under the ongoing PHEIC. Remdesivir, MBP-134, and maftivimab were prioritized for clinical treatment trials, while obeldesivir was recommended for post-exposure prophylaxis. The evaluation considered preclinical efficacy and safety data, including the PALM trial for Inmazeb."